Rare Disease Diagnostics Market, 2025: Path to Success - Partnerships and Coordinated Efforts of the Rare Diseases Community

DUBLIN, Nov. 12, 2018 /PRNewswire/ --

The "Global Rare Disease Diagnostics Market: Focus on Genetic Diseases, Service Providers, Competitive Landscape, and Country - Analysis and Forecast, 2018-2025" report has been added to ResearchAndMarkets.com's offering.

The global rare disease diagnostics market was valued $45.18 billion in 2017 and is anticipated to reach $86.15 billion by 2025

Factors such as high incidence of rare diseases, presence of large numbers of research and development facilities for rare diseases, significant number of rare disease registries, high diagnosis rare of rare diseases in countries of North America, and extensive investments in different therapeutic areas are driving the growth of the North America rare disease diagnostics market. However, the Asia Pacific region is expected to register the highest CAGR of 9.22% during the forecast period 2018-2025.

The purpose of the study is to gain a holistic view of the global rare disease diagnostics market in terms of various factors influencing it such as key market trends, competitive and regulatory aspects of the market, and scientific innovations with respect to gene sequencing. The scope of the report is centered upon conducting a detailed study of the diagnostic devices/services, assays used to diagnose rare diseases. Rare disease diagnosis involves wide range of diagnostic tests such as genetic tests, lab tests, imaging, physical examinations performed in diagnostic laboratories, hospitals, cancer research institutes and others. The rare disease diagnostics market is divided into six different segments: diseases, test type, trait, age, end user, and region. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

The global rare disease diagnostics market (by disease type) is currently dominated by hematology and oncology segment. The contribution of hematology and oncology segment was valued $10.0 billion in 2017 and is expected to reach $20.5 billion by 2025, witnessing a CAGR of 9.35% during the forecast period.

Based on test type, the market is segmented into genetic tests, general lab tests, imaging, and other physical tests for rare diseases. Rare diseases are difficult to diagnose and according to NIH, as many as 80 % of rare diseases are genetic in origin, thus often requiring genetic test for diagnosis

Based on the trait type, the market is segmented into inherited and acquired. Based on the age group, the market is segmented into children and adults. About 80% of rare diseases are not acquired, they are inherited or has predisposition of faulty gene. The average time to diagnosis is approximately 5-6 years and 40% of rare diseases are misdiagnosed. Children account for 50 % of rare disease patients. According to the Canadian Organization of Rare Diseases, two-third of Canadians suffering from rare disease are children. Another extremely unfortunate fact is that thirty percent of children with rare diseases are not likely to reach their fifth birthday.

Geographically, the market is segmented into five distinct regions including North America, Europe, Asia-Pacific, Latin America, and Middle East Africa (MEA). North America, followed by Europe, is the leading contributor of the market. Within North America, the U.S. contributed for almost 91.12% of the total share, and the rest was occupied by Canada in 2017. Within Europe, the U.K dominated the market in 2017. However, the market for the Asia-pacific region is expected to demonstrate high growth rate during the forecast period from 2018 to 2025, as compared to other regions, and the region holds a strong potential for market expansion in the future.

The rare disease diagnostics market (by genetic tests) has a promising potential for growth in the coming years. The report provides an in-depth SWOT analysis of different key players of the market, supported by extensive financial summary of each company.

The key players of the market include Retrophin, Inc., QIAGEN N.V., Illumina Inc., PerkinElmer, Inc., BGI, Partek, Inc., Centogene A.G., Strand Life Sciences Pvt Ltd., Eurofins Scientific, Laboratory Corporation of America, and Laboratory Corporation of America, among others.

Key Topics Covered:

Executive Summary

1 Market Overview
1.1 Rare Disease Introduction
1.2 Tests Performed during Diagnosis
1.3 Rare Disease Challenges and Recommendations
1.4 List of Genetic Tests
1.5 Rare Disease Policies
1.6 A Path to Success: Partnerships and Coordinated Efforts of the Rare Diseases Community
1.7 Global Market Overview
1.8 Assumptions and Limitations

2 Market Dynamics
2.1 Market Dynamics: Drivers, Restraints, and Opportunities, and Trends
2.2 Rare Disease Diagnostics Market: Drivers
2.3 Rare Disease Diagnostics Market: Challenges
2.4 Rare Disease Diagnostics Market: Opportunity
2.5 Rare Disease Diagnostics Market: Trends

3 Competitive Landscape
3.1 Product Launches
3.2 Joint Venture, Collaborations, and Partnerships
3.3 IRDiRC Perspective: Progress in Rare Diseases Research, 2010-2016
3.4 Service Providers

4 Industry Insights
4.1 Funding Scenario
4.2 Legal Requirements and Regulations
4.3 List of Regulatory Bodies

5 Global Rare Disease Diagnostics Market (by Disease Type)
5.1 Key Takeaways
5.2 Rare Disease Market Attractiveness (by Disease Type)
5.3 Overview: Disease Type
5.4 Market Overview: Disease Type
5.5 Market Value (by Gastroenterology Disease Type), 2017-2025
5.6 Market Value ((by Endocrine and Metabolism Disorders Disease Type)), 2017-2025
5.7 Market Value (by Cardiovascular Disorders), 2017-2025
5.8 Market Value (by Neurology Disease Type), 2017-2025
5.9 Market Value (by Hematology and Oncology Disease Type), 2017-2025
5.10 Market Value (by Dermatology Disease Type), 2017-2025
5.11 Market Value (by Other Therapeutic Areas), 2017-2025

6 Global Rare Disease Diagnostics Market (by Test Type)
6.1 Key Takeaways
6.2 Rare Disease Market Attractiveness (by Test Type)
6.3 Overview: Test Type
6.4 Market Overview: Disease Type
6.5 Market Value (by Genetic Test Type), 2017-2025
6.6 Market Value (by General Lab Tests), 2017-2025
6.7 Market Value (by Imaging Test Type), 2017-2025
6.8 Market Value (by Other Tests), 2017-2025

7 Global Rare Disease Diagnostics Market (by Trait)
7.1 Key Takeaways
7.2 Rare Disease Market Attractiveness (by Trait Type)
7.3 Overview: Trait Type
7.4 Market Overview: Trait Type
7.5 Market Value (by Inherited Trait Type), 2017-2025
7.6 Market Value (by Acquired Trait Type), 2017-2025

8 Global Rare Disease Diagnostics Market (by Age Group)
8.1 Key Takeaways
8.2 Rare Disease Market Attractiveness (by Age Group)
8.3 Overview: Age Group
8.4 Market Overview: Age Group
8.5 Market Value (by Children Age Group), 2017-2025
8.6 Market Value (by Adult Age Group), 2017-2025

9 Global Rare Disease Diagnostics Market (by End User)
9.1 Key Takeaways
9.2 Rare Disease Market Attractiveness (by End User)
9.3 Market Overview: End User
9.4 Market Value (by Hospital Laboratories), 2017-2025
9.5 Market Value (by Diagnostic laboratories), 2017-2025
9.6 Market Value (by Genetic Testing Laboratories), 2017-2025
9.7 Market Value (by Cancer Research Laboratories), 2017-2025
9.8 Market Value (by Other End User), 2017-2025

10 Global Rare Disease Diagnostics Market (by Region)
10.1 Market Overview (by Region)
10.2 Global Rare Disease Diagnostics Market (by Region)
10.3 Market Value (by Region)

11 North America Rare Disease Diagnostics Market

12 Europe Rare Disease Diagnostics Market

13 Latin America Rare Disease Diagnostics Market

14 Asia Pacific Rare Disease Diagnostics Market

15 MEA Rare Disease Diagnostics Market

16 Company Profiles

• 23andMe, Inc.
• 3billion, Inc.
• BGI
• Centogene A.G.
• Eurofins Scientific
• GENEWIZ
• Illumina Inc.
• InDepth Genomics
• Laboratory Corporation of America
• Partek, Inc.
• PerkinElmer, Inc.
• Personal Genome Diagnostics, Inc.
• QIAGEN N.V.
• Retrophin, Inc.
• Strand Life Sciences Pvt Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/pp73bp/rare_disease?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com